息肉样脉络膜视网膜病变患者泪液p38 MAPK mRNA、 Sirt1 mRNA水平与康柏西普治疗效果的关系  

Relationship between p38 MAPK mRNA and Sirt1 mRNA levels in tears with Conbercept therapeutic effect in patients with polypoidal choroidal vasculopathy

作　　者：张亚妮 程万英 阿依努·努拉厚 ZHANG Yani;CHENG Wanying;AYINU Nulahou(Department of Ophthalmology,Traditional Chinese Medicine Hospital of Xinjiang Uygur Autonomous Region,Urumqi,Xinjiang 830000,China)

机构地区：[1]新疆维吾尔自治区中医医院眼科,新疆乌鲁木齐830000

出　　处：《检验医学与临床》2024年第14期2034-2039,共6页Laboratory Medicine and Clinic

基　　金：新疆维吾尔自治区科学技术厅基金项目(2022D03053)。

摘　　要：目的探讨息肉样脉络膜视网膜病变(PCV)患者泪液p38丝裂原活化蛋白激酶(MAPK)mRNA、沉默信息调节因子2相关酶1(Sirt1)mRNA水平与康柏西普治疗效果的关系。方法选取2020年8月至2022年4月该院94例PCV患者作为观察组,根据康柏西普治疗效果分为效果良好亚组、效果较差亚组,选取同期年龄、性别匹配的健康体检者94例作为对照组。2组均检测泪液p38 MAPK mRNA、Sirt1 mRNA及血管内皮生长因子(VEGF)水平。分析泪液p38 MAPK mRNA、Sirt1 mRNA水平与VEGF的相关性。采用受试者工作特征(ROC)曲线分析泪液p38 MAPK mRNA、Sirt1 mRNA及VEGF对康柏西普治疗效果的预测价值。采用多因素Logistic回归分析康柏西普治疗效果的影响因素。结果观察组治疗前、治疗12周泪液p38 MAPK mRNA及VEGF水平高于对照组,Sirt1 mRNA水平低于对照组,差异均有统计学意义(P<0.05);观察组治疗12周泪液p38 MAPK mRNA及VEGF水平低于治疗前,Sirt1 mRNA水平高于治疗前,差异均有统计学意义(P<0.05)。治疗前、治疗12周泪液p38 MAPK mRNA水平与VEGF水平呈正相关(r=0.717、0.338,P<0.001),治疗前、治疗12周泪液Sirt1 mRNA水平与VEGF水平呈负相关(r=-0.766、-0.396,P<0.001)。94例PCV患者随访1年,息肉完全消退率为40.66%。效果较差亚组治疗前、治疗12周p38 MAPK mRNA及VEGF水平高于效果良好亚组,Sirt1 mRNA水平低于效果良好亚组,差异均有统计学意义(P<0.05)。治疗12周泪液p38 MAPK mRNA、Sirt1 mRNA及VEGF联合预测PCV患者康柏西普治疗效果的曲线下面积(AUC)大于单项指标预测的AUC(P<0.05)。p38 MAPK mRNA、Sirt1 mRNA均是PCV患者康柏西普治疗效果的影响因素(P<0.05)。结论PCV患者p38 MAPK mRNA、Sirt1 mRNA表达异常,二者均与康柏西普治疗效果有关。Objective To investigate the relationship between the levels of p38 mitogen-activated protein kinase(MAPK)mRNA and silencing information regulatory factor 2 related enzyme 1(Sirt1)mRNA with the Conbercept therapeutic effect in the patients with polypoidal choroidal vasculopathy(PCV).Methods A total of 94 patients with PCV in this hospital from August 2020 to April 2022 were selected as the observation group and divided into the good effect subgroup and poor effect subgroup according to the Conbercept therapeutic effect.In the same period,94 age and gender matched healthy subjects undergoing physical examination served as the control group.The levels of tear p38 MAPK mRNA,Sirt1 mRNA and vascular endothelial growth factor(VEGF)were detected in both groups.The correlation between tear p38 MAPK mRNA and Sirt1 mRNA with VEGF was analyzed.The receiver operating characteristic(ROC)curve was used to analyze the predictive value of p38 MAPK mRNA,Sirt1 mRNA and VEGF levels in the Conbercept therapeutic effect.The multivariate Logistic regression was used to analyze the influencing factors of the Conbercept therapeutic effect.Results The levels of tear p38 MAPK mRNA and VEGF before treatment and after 12-week treatment in the observation group were higher than those in the control group,the Sirt1 mRNA level was lower than that in the control group,and the differences were statistically significant(P<0.05).The levels of tear p38 MAPK mRNA and VEGF after 12-week treatment in the observation group were lower than those before treatment,and the Sirt1 mRNA level was higher than that before treatment,and the differences were statistically significant(P<0.05).The p38 MAPK mRNA levels before treatment and after 12-week treatment were positively correlated with VEGF(r=0.717,0.338,P<0.001)and the Sirt1 mRNA levels before treatment and after 12-week treatment were negatively correlated with VEGF(r=-0.766,-0.396,P<0.001).Ninety-four patients with PCV were followed up for 1 year,and the complete subsided rate of polyps was 40.66%.The le

关 键 词：息肉样脉络膜视网膜病变 p38丝裂原活化蛋白激酶 沉默信息调节因子2相关酶1 康柏西普 泪液 

分 类 号：R773.4[医药卫生—眼科] R446.9[医药卫生—临床医学]